XYL Xylem Inc.
Quality water franchise with margin upside, but slowing growth means the price still assumes too much
The story
Xylem is the scaled pure-play in water technology: pumps, treatment (Evoqua), metering and analytics, sold into utilities and industrial customers with a large, sticky installed base and recurring aftermarket and service revenue. It is a mature compounder. Integrating Evoqua and simplifying the portfolio with 80/20 pruning are lifting margins, while organic top-line growth has slowed to low-to-mid single digits. The moat is real but moderate (brand, installed base, utility specification lock-in), so this is a 10-year runway, not a 15-year franchise.
I cut year-1 growth from 7% to 5% because TTM revenue grew only about 1% (9.04B to 9.13B) as 80/20 product exits and soft China and treatment demand weighed. The 18% target margin holds: TTM GAAP margin rose to 14.2% and still carries roughly 3-4 points of Evoqua amortization, so 18% reflects sustainable peer-level economics, not peak pricing. Sales-to-capital stays at 0.8, above the goodwill-depressed 0.68 reported figure, because incremental growth needs far less capital than the Evoqua purchase did; beta stays at the 1.05 industry anchor.
Value drivers
| Revenue growth (Y1) | 5.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 10y |
| Target operating margin | 18.0% |
| Years to target margin | 7 |
| Sales-to-capital | 0.80 |
| Beta | 1.05 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 9.7% |
| Terminal WACC | 9.5% |
Valuation bridge
| PV of explicit FCFF | 5.97B |
| PV of terminal value | 8.45B |
| Equity value | 13.56B |
| ÷ shares → per share | $58.05 |
News
bearish -0.30 · 8 articles
- Here's Why You Should Retain Xylem Stock in Your Portfolio Now
- Xylem (XYL) Stock Could Be 35% Undervalued As Cash Flow Holds Up
- Xylem (XYL) Raises $1.5b As Undervalued Narrative Faces A Market Test
- 2 Mid-Cap Stocks with Competitive Advantages and 1 Facing Headwinds
- Custom Truck One Source, Terex, Xylem, Onterris, and Oshkosh Shares Plummet, What You Need To Know
- Xylem Stock: Is XYL Underperforming the Industrial Sector?
- Xylem (XYL) Down 7.1% Since Last Earnings Report: Can It Rebound?
- GE HealthCare Technologies (GEHC) Names A New CFO As Its Undervalued Narrative Faces A Test
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 9.58B | 5.0% | 14.7% | 1.14B | 570.38M | 566.09M | 516.16M |
| 2 | 10.04B | 4.8% | 15.3% | 1.23B | 572.28M | 662.31M | 550.64M |
| 3 | 10.50B | 4.6% | 15.8% | 1.34B | 571.73M | 764.93M | 579.87M |
| 4 | 10.95B | 4.3% | 16.4% | 1.44B | 568.61M | 873.78M | 603.96M |
| 5 | 11.40B | 4.1% | 16.9% | 1.55B | 562.83M | 988.63M | 623.09M |
| 6 | 11.85B | 3.9% | 17.5% | 1.66B | 554.30M | 1.11B | 637.43M |
| 7 | 12.28B | 3.7% | 18.0% | 1.78B | 542.95M | 1.24B | 647.21M |
| 8 | 12.70B | 3.4% | 18.0% | 1.84B | 528.74M | 1.31B | 626.18M |
| 9 | 13.11B | 3.2% | 18.0% | 1.90B | 511.67M | 1.39B | 604.21M |
| 10 | 13.51B | 3.0% | 18.0% | 1.96B | 491.73M | 1.46B | 581.47M |
Key risks
- Organic growth stalls in low single digits as utility capex and China/industrial demand stay soft
- Margin expansion plateaus near 15-16% if 80/20 savings get reinvested or pricing power fades
- The $1.5B raise funds an expensive acquisition that dilutes returns on capital
Catalysts
- Evidence that 80/20 simplification pushes GAAP operating margin toward 16%+ with revenue reaccelerating
- US water infrastructure spending, PFAS treatment mandates, and data-center cooling-water demand driving treatment and metering orders